106 related articles for article (PubMed ID: 7667323)
1. Intratumoral injection of an adenovirus expressing interleukin 2 induces regression and immunity in a murine breast cancer model.
Addison CL; Braciak T; Ralston R; Muller WJ; Gauldie J; Graham FL
Proc Natl Acad Sci U S A; 1995 Aug; 92(18):8522-6. PubMed ID: 7667323
[TBL] [Abstract][Full Text] [Related]
2. Antitumor activity with nontoxic doses of protein A.
Ray PK; Bandyopadhyay S; Dohadwala M; Canchanapan P; Mobini J
Cancer Immunol Immunother; 1984; 18(1):29-34. PubMed ID: 6567477
[TBL] [Abstract][Full Text] [Related]
3. Intratumoral delivery of immunotherapy to treat breast cancer: current development in clinical and preclinical studies.
Mantooth SM; Abdou Y; Saez-Ibañez AR; Upadhaya S; Zaharoff DA
Front Immunol; 2024; 15():1385484. PubMed ID: 38803496
[TBL] [Abstract][Full Text] [Related]
4. Replication Study: The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors.
Horrigan SK;
Elife; 2017 Jan; 6():. PubMed ID: 28100392
[TBL] [Abstract][Full Text] [Related]
5. Adenoviral Delivery of Tumor Necrosis Factor-α and Interleukin-2 Enables Successful Adoptive Cell Therapy of Immunosuppressive Melanoma.
Siurala M; Havunen R; Saha D; Lumen D; Airaksinen AJ; Tähtinen S; Cervera-Carrascon V; Bramante S; Parviainen S; Vähä-Koskela M; Kanerva A; Hemminki A
Mol Ther; 2016 Aug; 24(8):1435-43. PubMed ID: 27357626
[TBL] [Abstract][Full Text] [Related]
6. Breast cancer gene therapy using an adenovirus encoding human IL-2 under control of mammaglobin promoter/enhancer sequences.
Chaurasiya S; Hew P; Crosley P; Sharon D; Potts K; Agopsowicz K; Long M; Shi C; Hitt MM
Cancer Gene Ther; 2016 Jun; 23(6):178-87. PubMed ID: 27151235
[TBL] [Abstract][Full Text] [Related]
7. Challenges and developing solutions for increasing the benefits of IL-2 treatment in tumor therapy.
Skrombolas D; Frelinger JG
Expert Rev Clin Immunol; 2014 Feb; 10(2):207-17. PubMed ID: 24410537
[TBL] [Abstract][Full Text] [Related]
8. Comparative functional evaluation of immunocompetent mouse breast cancer models established from PyMT-tumors using small animal PET with [(18)F]FDG and [(18)F]FLT.
Desilva A; Wuest M; Wang M; Hummel J; Mossman K; Wuest F; Hitt MM
Am J Nucl Med Mol Imaging; 2012; 2(1):88-98. PubMed ID: 23133804
[TBL] [Abstract][Full Text] [Related]
9. The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors.
Willingham SB; Volkmer JP; Gentles AJ; Sahoo D; Dalerba P; Mitra SS; Wang J; Contreras-Trujillo H; Martin R; Cohen JD; Lovelace P; Scheeren FA; Chao MP; Weiskopf K; Tang C; Volkmer AK; Naik TJ; Storm TA; Mosley AR; Edris B; Schmid SM; Sun CK; Chua MS; Murillo O; Rajendran P; Cha AC; Chin RK; Kim D; Adorno M; Raveh T; Tseng D; Jaiswal S; Enger PØ; Steinberg GK; Li G; So SK; Majeti R; Harsh GR; van de Rijn M; Teng NN; Sunwoo JB; Alizadeh AA; Clarke MF; Weissman IL
Proc Natl Acad Sci U S A; 2012 Apr; 109(17):6662-7. PubMed ID: 22451913
[TBL] [Abstract][Full Text] [Related]
10. EphrinA1-EphA2 interaction-mediated apoptosis and FMS-like tyrosine kinase 3 receptor ligand-induced immunotherapy inhibit tumor growth in a breast cancer mouse model.
Tandon M; Vemula SV; Sharma A; Ahi YS; Mittal S; Bangari DS; Mittal SK
J Gene Med; 2012 Feb; 14(2):77-89. PubMed ID: 22228563
[TBL] [Abstract][Full Text] [Related]
11. Development of an attenuated interleukin-2 fusion protein that can be activated by tumour-expressed proteases.
Puskas J; Skrombolas D; Sedlacek A; Lord E; Sullivan M; Frelinger J
Immunology; 2011 Jun; 133(2):206-20. PubMed ID: 21426339
[TBL] [Abstract][Full Text] [Related]
12. Immune therapy for breast cancer in 2010-hype or hope?
Florescu A; Amir E; Bouganim N; Clemons M
Curr Oncol; 2011 Jan; 18(1):e9-e18. PubMed ID: 21331271
[TBL] [Abstract][Full Text] [Related]
13. Emerging strategies for EphA2 receptor targeting for cancer therapeutics.
Tandon M; Vemula SV; Mittal SK
Expert Opin Ther Targets; 2011 Jan; 15(1):31-51. PubMed ID: 21142802
[TBL] [Abstract][Full Text] [Related]
14. CD4+ T-cell help in the tumor milieu is required for recruitment and cytolytic function of CD8+ T lymphocytes.
Bos R; Sherman LA
Cancer Res; 2010 Nov; 70(21):8368-77. PubMed ID: 20940398
[TBL] [Abstract][Full Text] [Related]
15. Adenoviral vector-based strategies for cancer therapy.
Sharma A; Tandon M; Bangari DS; Mittal SK
Curr Drug ther; 2009 May; 4(2):117-138. PubMed ID: 20160875
[TBL] [Abstract][Full Text] [Related]
16. Comparative analysis of vector biodistribution, persistence and gene expression following intravenous delivery of bovine, porcine and human adenoviral vectors in a mouse model.
Sharma A; Bangari DS; Tandon M; Pandey A; HogenEsch H; Mittal SK
Virology; 2009 Mar; 386(1):44-54. PubMed ID: 19211122
[TBL] [Abstract][Full Text] [Related]
17. One-year expression from high-capacity adenoviral vectors in the brains of animals with pre-existing anti-adenoviral immunity: clinical implications.
Barcia C; Jimenez-Dalmaroni M; Kroeger KM; Puntel M; Rapaport AJ; Larocque D; King GD; Johnson SA; Liu C; Xiong W; Candolfi M; Mondkar S; Ng P; Palmer D; Castro MG; Lowenstein PR
Mol Ther; 2007 Dec; 15(12):2154-63. PubMed ID: 17895861
[TBL] [Abstract][Full Text] [Related]
18. Effects of recombinant adenovirus-mediated expression of IL-2 and IL-12 in human B lymphoma cells on co-cultured PBMC.
Ebert O; Wilbert D; Buttgereit P; Ziske C; Flieger D; Schmidt-Wolf IG
Genet Vaccines Ther; 2004 Oct; 2(1):15. PubMed ID: 15485577
[TBL] [Abstract][Full Text] [Related]
19. CXC chemokine ligand 10 controls viral infection in the central nervous system: evidence for a role in innate immune response through recruitment and activation of natural killer cells.
Trifilo MJ; Montalto-Morrison C; Stiles LN; Hurst KR; Hardison JL; Manning JE; Masters PS; Lane TE
J Virol; 2004 Jan; 78(2):585-94. PubMed ID: 14694090
[TBL] [Abstract][Full Text] [Related]
20. Oestradiol enhances tumour regression induced by B7-1/IL-2 adenoviral gene transfer in a murine model of breast cancer.
Dabrosin C; Palmer K; Gauldie J
Br J Cancer; 2003 Jul; 89(2):385-90. PubMed ID: 12865933
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
